Ozekibart Achieves Primary Endpoint in Chondrosarcoma, Showing Strong Efficacy and Safety Results

Clinical trial results show Inhibrx’s Ozekibart significantly improves survival measures in advanced chondrosarcoma, where no approved options exist, and demonstrates encouraging high response rates in colorectal cancer and Ewing sarcoma.